US Stock MarketDetailed Quotes
DYN Dyne Therapeutics
- 42.530
- +1.060+2.56%
Trading Jul 22 13:28 ET
4.23BMarket Cap-10685P/E (TTM)
42.690High41.360Low326.49KVolume41.630Open41.470Pre Close13.74MTurnover0.39%Turnover RatioLossP/E (Static)99.46MShares44.33052wk High8.85P/B3.54BFloat Cap6.40052wk Low--Dividend TTM83.32MShs Float44.330Historical High--Div YieldTTM3.21%Amplitude4.300Historical Low42.096Avg Price1Lot Size
About Dyne Therapeutics Company
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Company Profile
SymbolDYN
Company NameDyne Therapeutics
Listing DateSep 17, 2020
Issue Price19.00
Founded2017
CEOMr. John G. Cox
MarketNASDAQ
Employees141
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address830 Winter Street
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02451
Phone1-781-786-8230
Websitehttp://www.dyne-tx.com
Company Executives
- Name
- Position
- Salary
- John G. Cox
- Director, President and Chief Executive Officer
- --
- Dr. Oxana Beskrovnaya, PhD
- Chief Scientific Officer
- --
- Wildon Farwell, M.D.,M.P.H.
- Chief Medical Officer
- --
- Susanna High
- Chief Operating Officer
- 2.05M
- Dr. Jonathan McNeill, M.D.
- Chief Business Officer
- 2.23M
- Richard William Scalzo
- Senior Vice President, Head of Finance and Administration, Principal Financial and Accounting Officer
- --
- Jason P. Rhodes
- Chairman of the Board
- 283.17K
- Edward M. Hurwitz, J.D.
- Independent Director
- 250.17K
- Dirk Kersten
- Independent Director
- 262.67K
- David Charles Lubner, C.P.A.,M.S.
- Independent Director
- 264.17K
- Dr. Carlo Incerti
- Independent Director
- 250.17K
- Dr. Catherine Stehman-Breen, M.D.
- Independent Director
- 253.92K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg